Biotech · Private company
Celcuity Inc
Track this companyFree. Adds Celcuity Inc to your Dealase workspace and tells you when its record changes.
Clinical trials105 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline12
- AlpelisibPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Arm A: Gedatolisib + Palbociclib + FulvestrantPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Arm B: Ribociclib + FulvestrantPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Arm C: Gedatolisib + Palbociclib + LetrozolePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- Arm D: Ribociclib + LetrozolePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- FulvestrantPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GedatolisibPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- PalbociclibPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- DarolutamidePhase 2 · mCRPC (Metastatic Castration-resistant Prostate Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- GedatolisibPhase 2 · mCRPC (Metastatic Castration-resistant Prostate Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- LetrozolePhase 1 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- GedatolisibBreast Neoplasm Malignant FemaleClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)PHASE3 · RECRUITING · started Jul 24, 2025ClinicalTrials.gov NCT06757634 · fetched Nov 12, 2026
- Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate CancerPHASE1_PHASE2 · RECRUITING · started Jan 1, 2024ClinicalTrials.gov NCT06190899 · fetched Nov 12, 2026
- Fulvestrant + Neratinib In Breast CancerPHASE2 · WITHDRAWN · started Jul 1, 2023ClinicalTrials.gov NCT04901299 · fetched Nov 12, 2026
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 8, 2022ClinicalTrials.gov NCT05501886 · fetched Nov 12, 2026
- Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis TestPHASE1_PHASE2 · TERMINATED · started Aug 18, 2022ClinicalTrials.gov NCT05243641 · fetched Nov 12, 2026
- Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative BreastPHASE2 · UNKNOWN · started Jun 21, 2019ClinicalTrials.gov NCT03812393 · fetched Nov 12, 2026
- Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Apr 17, 2019ClinicalTrials.gov NCT03911973 · fetched Nov 12, 2026
- RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial CancerPHASE2 · RECRUITING · started Dec 24, 2018ClinicalTrials.gov NCT03675893 · fetched Nov 12, 2026
- A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast CancerPHASE1 · COMPLETED · started Jun 14, 2016ClinicalTrials.gov NCT02684032 · fetched Nov 12, 2026
- Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009AVAILABLEClinicalTrials.gov NCT05134922 · fetched Nov 12, 2026